Apolipoprotein alleles and the response to interferon-β-1b in multiple sclerosis

European Neurology

Volumn 65, Issue 3, 2011, Pages 132-137

  Carmona, Olga ^a,c   Masuet, Cristina ^b   Alía, Pedro ^c   Moral, Ester ^a   Alonso Magdalena, Lucía ^a   Casado, Virginia ^a   Martín Ozaeta, Gisela ^a   Arbizu, Txomin ^a  

^a Multiple Sclerosis Unit   (Spain)

^b Preventive Medicine Department   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

ApoE genotype; Disability; Interferon beta; Multiple sclerosis

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; INTERFERON BETA SERINE;

ADULT; ALLELE; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COGNITIVE DEFECT; COHORT ANALYSIS; DISEASE COURSE; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; TREATMENT RESPONSE;

ADULT; ALLELES; APOLIPOPROTEINS E; DISABILITY EVALUATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; LONGITUDINAL STUDIES; MALE; MULTIPLE SCLEROSIS; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79851514545     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323982     Document Type: Article

References (27)

1. Carlin C, Murray L, Graham D, Doyle D, Nicoll J: Involvement of apolipoprotein E in multiple sclerosis: absence of remyelination associated with possession of the ApoE 2 allele. J Neuropathol Exp Neurol 2000; 59: 361-367. (Pubitemid 30257565)
2. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-Mac Lachlan DR, Alberts MJ, et al: Association of apolipoprotein E alleleε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472. (Pubitemid 23230526)
3. Dik MG, Jonker C, Comijs HC, Bouter LM, Twisk JW, van Kamp GJ, Deeg DJ: Memory complaints and ApoE-ε4 accelerate cognitive decline in cognitively normal elderly. Neurology 2001; 57: 2217-2222. (Pubitemid 34016454)
4. Burwick RM, Ramsay PP, Haines JL, Hauser SL, Oksenberg JR, Pericak-Vance MA, Schmidt S, Compston A, Sawcer S, Cittadella R, Savettieri G, Quattrone A, Polman CH, Uitdehaag BM, Zwemmer JN, Hawkins CP, Ollier WE, Weatherby S, Enzinger C, Fazekas F, Schmidt H, Schmidt R, Hillert J, Masterman T, Hogh P, Niino M, Kikuchi S, Maciel P, Santos M, Rio ME, Kwiecinski H, Zakrzewska- Pniewska B, Evangelou N, Palace J, Barcellos LF: ApoEε variation in multiple sclerosis susceptibility and disease severity: some answers. Neurology 2006; 66: 1373-1383. (Pubitemid 43739647)
5. Schmidt S, Barcellos LF, DeSombre K, Rimmler JB, Lincoln RR, Bucher P, Saunders AM, Lai E, Martin ER, Vance JM, Oksenberg JR, Hauser SL, Pericak-Vance MA, Haines JL, Multiple Sclerosis Genetics Group: Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am J Hum Genet 2002; 70: 708-717. (Pubitemid 34177924)
6. Weatherby SJ, Mann CL, Davies MB, Carthy D, Fryer AA, Boggild MD, Young C, Strange RC, Ollier W, Hawkins CP: Polymorphisms of apolipoprotein E: outcome and susceptibility in multiple sclerosis. Mult Scler 2000; 6: 32-36. (Pubitemid 30175369)
7. Guerrero AL, Laherrán E, Gutiérrez F, Martín- Polo J, Iglesias F, Alcázar C, Peralta J, Rostami P: Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score. Acta Neurol Scand 2008; 117: 21-25. (Pubitemid 350264504)
8. Sedano MJ, Calmarza P, Perez L, Trejo JM: No association of apolipoprotein Eε4 genotype with faster progression or less recovery of relapses in Spanish cohort of multiple sclerosis. Mult Scler 2006; 12: 13-18. (Pubitemid 43169233)
9. Guerrero AL, Bueno V, Hernandez MT, Martin-Serradilla JI, Carrasco E, Cuadrado I: Apolipoprotein E polymorphism as a predictor of progression of multiple sclerosis (in Spanish). Neurología 2003; 18: 146-148. (Pubitemid 36514188)
10. Pinholt M, Frederiksen JL, Andersen PS, Christiansen M: ApoE in multiple sclerosis and optic neuritis: the ApoE-ε4 allele is associated with progression in multiple sclerosis. Mult Scler 2005; 11: 511-515. (Pubitemid 41387693)
11. Savettieri G, Andreoli V, Bonavita S, Cittadella R, Caltagirone C, Fazio MC, Girlanda P, Le Pira F, Liguori M, Logroscino G, Lugaresi A, Nocentini U, Reggio A, Salemi G, Serra P, Tedeschi G, Toma L, Trojano M, Valentino P, Quattrone A: Apolipoprotein E genotype does not influence the progression of multiple sclerosis. J Neurol 2003; 250: 1094-1098. (Pubitemid 37168017)
12. Kantarci OH, Hebrink DD, Achenbach SJ, Pittock SJ, Altintas A, Schaefer-Klein JL, Atkinson EJ, De Andrade M, McMurray CT, Rodriguez M, Weinshenker BG: Association of ApoE polymorphisms with disease severity in MS is limited to women. Neurology 2004; 62: 811-814. (Pubitemid 38298966)
13. Zakrzewska-Pniewska B, Styczynska M, Podlecka A, Samocka R, Peplonska B, Barcikowska M, Kwiecinski H: Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis. Mult Scler 2004; 10: 266-271. (Pubitemid 38807452)
14. Masterman T, Zhang Z, Hellgren D, Salter H, Anvret M, Lilius L, Lannfelt L, Hillert J: ApoE genotypes and disease severity in multiple sclerosis. Mult Scler 2002; 8: 98-103. (Pubitemid 34256744)
15. Chapman J, Vinokurov S, Achiron A, Karussis DM, Mitosek-Szewczyk K, Birnbaum M, Michaelson DM, Korczyn AD: ApoE genotype is a major predictor of long-term progression of disability in MS. Neurology 2001; 56: 312-316. (Pubitemid 32144140)
16. Fazekas F, Strasser-Fuchs S, Kollegger H, Berger T, Kristoferitsch W, Schmidt H, Enzinger C, Schiefermeier M, Schwarz C, Kornek B, Reindl M, Huber K, Grass R, Wimmer G, Vass K, Pfeiffer KH, Hartung HP, Schmidt R: Apolipoprotein E-ε4 is associated with rapid progression of multiple sclerosis. Neurology 2001; 57: 853-857. (Pubitemid 32845507)
17. Enzinger C, Ropele S, Smith S, Strasser- Fuchs S, Poltrum B, Schmidt H, Matthews PM, Fazekas F: Accelerated evolution of brain atrophy and 'black holes' in MS patients with ApoE-ε4. Ann Neurol 2004; 55: 563-569. (Pubitemid 38391974)
18. Enzinger C, Ropele S, Strasser-Fuchs S, Kapeller P, Schmidt H, Poltrum B, Schmidt R, Hartung HP, Fazekas F: Lower levels of Nacetylaspartate in multiple sclerosis patients with the apolipoprotein E-ε4 allele. Arch Neurol 2003; 60: 65-70. (Pubitemid 36078110)
19. Schreiber K, Otura AB, Ryder LP, Madsen HO, Jørgensen OS, Svejgaard A, Sorensen PS: Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRBI, CCR5 deletion mutation, apolipoprotein E). Mult Scler 2002; 8: 295-298. (Pubitemid 34784756)
20. De Stefano N, Bartolozzi ML, Nacmias B, Zipoli V, Mortilla M, Guidi L, Siracusa G, Sorbi S, Federico A, Amato MP: Influence of apolipoprotein E4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. Arch Neurol 2004; 61: 536-540. (Pubitemid 38923743)
21. Savettieri G, Messina D, Andreoli V, Bonavita S, Caltagirone C, Cittadella R, Farina D, Fazio MC, Girlanda P, Le Pira F, Liguori M, Lugaresi A, Nocentini U, Reggio A, Salemi G, Tedeschi G, Trojano M, Valentino P, Quattrone A: Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J Neurol 2004; 251: 1208-1214. (Pubitemid 39517923)
22. Oliveri RL, Cittadella R, Sibilia G, Manna I, Valentino P, Gambardella A, Aguglia U, Zappia M, Romeo N, Andreoli V, Bono F, Caracciolo M, Quattrone A: ApoE and risk of cognitive impairment in multiple sclerosis. Acta Neurol Scand 1999; 100: 290-295. (Pubitemid 29482551)
23. Ballerini C, Campani D, Rombolà G, Gran B, Nacmias B, Amato MP, Siracusa G, Bartolozzi L, Sorbi S, Massacesi L: Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis. Neurosci Lett 2000; 296: 174-176.
24. Lanzillo R, Prinster A, Scarano V, Liuzzi R, Coppola G, Florio C, Salvatore E, Schiavone V, Brunetti A, Muto M, Orefice G, Alfano B, Bonavita V, Brescia Morra V: Neuropsychological assessment, quantitative MRI and poE gene polymorphisms in a series of MS patients treated with IFNβ-1b. J Neurol Sci 2006; 15;245: 141-145. (Pubitemid 43775937)
25. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ: EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55: 671-676.
26. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-548. (Pubitemid 20107994)
27. Zintzaras E, Kitisios GD, Triposkiadis F, Lau J, Raman G: ApoE gene polymorphisms and response to statin therapy. Pharmacogenomics J 2009; 9: 248-257.